Baudax Bio (BXRX) Stock Price
Baudax Bio Price
Over the last 2 years Baudax Bio grew revenue by 61.0% annually, reaching 1.27 M USD. For Baudax Bio, the net margin of -4,629.9% is up versus -15,530.6% a few years ago. Of 6 analysts, 0 rate the stock a buy — an overall Sell consensus.
Baudax Bio stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Baudax Bio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Baudax Bio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Baudax Bio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Baudax Bio Price |
|---|
Baudax Bio Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Baudax Bio Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESk |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | 1.00 | 1.00 | – | – | – | 33.00 | 93.00 |
| – | – | – | – | – | – | – | – | – | – | 181.82 |
| – | – | – | – | -100.00 | -500.00 | – | – | – | -500.00 | -500.00 |
| -5.00 | -5.00 | -5.00 | -1.00 | -1.00 | -5.00 | -5.00 | -5.00 | -5.00 | -165.00 | -465.00 |
| -61.00 | -73.00 | -32.00 | -74.00 | -19.00 | -32.00 | -21.00 | -21.00 | -21.00 | -2.00 | 34.00 |
| – | – | – | – | -1,900.00 | -3,200.00 | – | – | – | -6.06 | 36.56 |
| -61.00 | -73.00 | -32.00 | -76.00 | -22.00 | -58.00 | -10.00 | -2.00 | -2.00 | – | 2.00 |
| – | 19.67 | -56.16 | 137.50 | -71.05 | 163.64 | -82.76 | -80.00 | – | – | – |
| 10.00 | 10.00 | 10.00 | 10.00 | 50.00 | 330.00 | 330.00 | 330.00 | 330.00 | 330.00 | 330.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Baudax Bio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Baudax Bio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Baudax Bio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Baudax Bio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Baudax Bio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Baudax Bio stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Baudax Bio Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Baudax Bio business model & stock analysis
Baudax Bio SWOT Analysis
Strengths
Baudax Bio Inc has a strong portfolio of innovative therapeutic products.
The company possesses a dedicated and highly-skilled research and development team.
Baudax Bio Inc enjoys a strong brand reputation in the pharmaceutical industry.
The company has established strategic partnerships with key stakeholders.
Weaknesses
Baudax Bio Inc is a relatively new entrant in the market, lacking the established market presence of competitors.
Limited financial resources may hinder the company's ability to expand rapidly.
The company's product pipeline is heavily reliant on a few key candidates, posing potential risks to future revenue streams.
Baudax Bio Inc faces challenges in capturing significant market share due to fierce competition.
Opportunities
The pharmaceutical industry is experiencing rapid growth, presenting opportunities for expansion for Baudax Bio Inc.
Emerging markets offer untapped potential for the company to introduce its products and gain market share.
Advancements in medical technology create opportunities for Baudax Bio Inc to develop innovative treatment options.
Mergers and acquisitions present opportunities for strategic partnerships and market consolidation.
Threats
Changing regulations and policies within the pharmaceutical industry can impact Baudax Bio Inc's operations.
Intense competition from established pharmaceutical companies poses a threat to market penetration and growth.
Economic fluctuations and uncertainty can negatively influence consumer spending on healthcare products.
The potential for legal and intellectual property disputes creates threats to Baudax Bio Inc's revenue streams.
Baudax Bio Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Baudax Bio historical P/E ratio, EBIT multiple, and P/S ratio
Baudax Bio annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Baudax Bio shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Baudax Bio stock splits
Current Baudax Bio forecasts and price targets in July 2026
Analyst Price Targets 2026| Δ MOM Price Target | 0.00 % |
| Buy | 0.00 % (0) |
| Hold | 50.00 % (3) |
| Sell | 50.00 % (3) |
| 12M Price Target | 24.48 |
| Last Price | 0.00 |
| Currency | USD |
| 12M Return Potential | 0 % |
| LTM Return | 0 % |
Baudax Bio Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 11/18/2024 | -0.09USD | -USD | 2024 Q3 |
| 5/10/2024 | -0.12USD | 0.00USD | 2024 Q1 |
| 2/21/2024 | -0.12USD | 0.00USD | 2023 Q4 |
| 11/6/2023 | -2.19USD | 242,584.00USD | 2023 Q3 |
| 8/9/2023 | -0.15USD | 2.45 MUSD | 2023 Q2 |
| 5/2/2023 | -0.26USD | 1.95 MUSD | 2023 Q1 |
| 3/14/2023 | -0.27USD | 1.58 MUSD | 2022 Q4 |
| 11/8/2022 | -0.54USD | 979,474.00USD | 2022 Q3 |
| 8/11/2022 | -1.30USD | 784,594.00USD | 2022 Q2 |
| 5/4/2022 | -1.89USD | 565,355.00USD | 2022 Q1 |
Baudax Bio shareholder structure
| % | Name |
|---|---|
7.78482% | |
0.75201% | |
0.65218% | |
0.18064% | |
0.16658% | |
0.02997% |
Frequently asked questions about Baudax Bio
The business model of Baudax Bio Inc revolves around the development and commercialization of pharmaceutical products. Baudax Bio focuses on acute care settings, specifically developing therapies for pain management. The company aims to address unmet medical needs by creating non-opioid alternatives for pain management, with a focus on post-operative pain. By leveraging innovative research and development strategies, Baudax Bio aims to bring novel and patient-centric therapies to market, improving the overall healthcare landscape. With a strong commitment to advancing medical solutions, Baudax Bio Inc is dedicated to positively impacting patient outcomes and revolutionizing pain management in the healthcare industry.
Baudax Bio stock
Baudax Bio Peer Group
Baudax Bio Ticker
Baudax Bio FIGI
All fundamentals and in-depth analysis of Baudax Bio
Our stock analysis for Baudax Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Baudax Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.